1. Home
  2. CRDL vs VABK Comparison

CRDL vs VABK Comparison

Compare CRDL & VABK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

N/A

Current Price

$1.85

Market Cap

226.6M

Sector

Health Care

ML Signal

N/A

Logo Virginia National Bankshares Corporation

VABK

Virginia National Bankshares Corporation

N/A

Current Price

$48.42

Market Cap

251.2M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
CRDL
VABK
Founded
2017
1998
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
226.6M
251.2M
IPO Year
2017
2013

Fundamental Metrics

Financial Performance
Metric
CRDL
VABK
Price
$1.85
$48.42
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
1.6M
2.7K
Earning Date
05-14-2026
04-23-2026
Dividend Yield
N/A
3.39%
EPS Growth
N/A
12.70
EPS
N/A
2.62
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$18.79
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$37.32
52 Week High
$2.34
$50.00

Technical Indicators

Market Signals
Indicator
CRDL
VABK
Relative Strength Index (RSI) 55.06 71.90
Support Level $0.97 $46.15
Resistance Level $2.28 $50.00
Average True Range (ATR) 0.16 0.63
MACD -0.03 0.23
Stochastic Oscillator 27.08 86.00

Price Performance

Historical Comparison
CRDL
VABK

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

About VABK Virginia National Bankshares Corporation

Virginia National Bankshares Corp is a bank holding company engaged in commercial and retail banking. The bank offers a range of banking and related financial services, including checking accounts, negotiable order of withdrawal accounts, money market deposit accounts, certificates of deposit, individual retirement accounts, and other depository services. Its segments include the Bank, VNB Trust and Estate Services, and Masonry Capital. The Bank's commercial banking activities involve making loans, taking deposits, and offering related services to individuals, businesses, and charitable organizations.

Share on Social Networks: